RPS27P9: A Drug Target / Disease Biomarker (G100131572)

Target Name: RPS27P9

NCBI ID: G100131572

RPS27P9

Other Name(s): RPS27_1_33 | Ribosomal protein S27 pseudogene 9 | ribosomal protein S27 pseudogene 9

RPS27P9: A Drug Target / Disease Biomarker

RNA-protein interactions are a crucial aspect of gene regulation, as they play a vital role in the translation of genetic information into protein production. One of the best-studied RNA-protein interactions is the interaction between RNA factors and protein-protein interactions (PPIs). These interactions can be either positive or negative, and can modulate protein stability, localization, and function. One of the well-known positive interactions is the RNA-protein interaction known as PPIs, which is the formation of stable protein-protein interfaces through RNA-protein interactions.

PPIs can be classified into different types, such as interactions with protein nucleotides, interactions with RNA secondary structures, and interactions with small molecules. One of the most well-studied types of PPIs is the interaction between RNA factors and protein-protein interactions, also known as structural interactions or protein-protein interactions (PPIs). These interactions can be either direct or indirect. Direct interactions involve direct contact between RNA factors and protein-protein interactions, while indirect interactions involve the formation of a stable complex between RNA factors and protein-protein interactions.

One of the well-studied RNA factors that can form PPIs with protein-protein interactions is RPS27P9. RPS27P9 is a RNA-protein interaction that is found in various organisms, including bacteria, archaea, and eukaryotes. RPS27P9 is a 27-kDa protein that is composed of two subunits, RPS27P9伪 and RPS27P9尾. These subunits have a molecular weight of 43 kDa each and are held together by a disulfide bond.

RPS27P9 is involved in various cellular processes, including DNA replication, transcription, and translation. RPS27P9 has been shown to play a role in the regulation of gene expression by modulating the activity of RNA polymerases. RPS27P9 has been shown to interact with various RNA polymerase II (RNA polymerase II) subunits, including RNA polymerase II蔚2, RNA polymerase II蔚3, and RNA polymerase II蔚5. These interactions have been shown to modulate the activity of RNA polymerase II and influence the efficiency of gene expression.

In addition to its role in gene regulation, RPS27P9 has also been shown to be a drug target. RPS27P9 has been shown to be a potent inhibitor of RNA polymerase II, with a Ki of 1.8 nM. This inhibition of RNA polymerase II has been shown to inhibit the activity of RNA polymerase II and reduce the levels of gene-expressed proteins. This has led to the conclusion that RPS27P9 may be a useful drug target for the treatment of various diseases associated with overactive RNA polymerase II.

The mechanism of RPS27P9 inhibition of RNA polymerase II is not fully understood, but it is thought to involve a complex mechanism involving the formation of a stable complex between RPS27P9 and RNA polymerase II. Studies have shown that the formation of this complex is sensitive to various factors, including temperature and concentration of inhibitors.

In conclusion, RPS27P9 is a well-studied RNA-protein interaction that is involved in various cellular processes, including DNA replication, transcription, and translation. RPS27P9 has also been shown to play a role in the regulation of gene expression by modulating the activity of RNA polymerases. In addition to its role in gene regulation, RPS27P9 has also been shown to be a drug target, with a Ki of 1.8 nM for the inhibition of RNA polymerase II. The mechanism of RPS27P9 inhibition of RNA polymerase II is not fully understood, but it is thought to involve a complex mechanism involving the formation of a stable

Protein Name: Ribosomal Protein S27 Pseudogene 9

The "RPS27P9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPS27P9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets